January 14, 2022
Sumitomo Dainippon Pharma has kicked off a US PI clinical study of the investigational drug candidate KSP-1007 for carbapenem-resistant bacterial infections, the company and its joint research partner Kitasato Institute said on January 13. The partners aim to develop the...read more